2023
608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors
Chen C, Hamilton E, LoRusso P, Rottey S, Papadopoulos K, Kummar S, Kotecki N, Thistlethwaite F, LeBruchec Y, Dyczkowski J, Rüschoff J, Samari S, Toukam M, Boni J, Havenith K, Pantano S, Puzanov I. 608 Results of a phase 1 study investigating camidanlumab tesirine as monotherapy and in combination with pembrolizumab in patients with selected advanced solid tumors. 2023, a692-a692. DOI: 10.1136/jitc-2023-sitc2023.0608.Peer-Reviewed Original Research1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma
Rodon J, Chaney M, Cohen J, Garyantes T, Ishizuka J, Lin J, Lorusso P, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S, Shoushtari A. 1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma. Annals Of Oncology 2023, 34: s663. DOI: 10.1016/j.annonc.2023.09.2235.Peer-Reviewed Original Research1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)
Olszanski A, Luke J, LoRusso P, Falchook G, Bedard P, Sanborn R, Patel S, Orr D, Gibbs J, Li C, Huang Y, Gregory R, Perera S, Xu R, Joshi A, Lee M, Raizer J, Gao X. 1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE). Annals Of Oncology 2023, 34: s625-s626. DOI: 10.1016/j.annonc.2023.09.2168.Peer-Reviewed Original Research
2022
759 Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors
Rodon J, Chaney M, Cohen J, Garyantes T, Lin J, Lorusso P, Mita A, Mita M, Muller C, Natale C, Orloff M, Papadopoulos K, Patel S. 759 Phase 1b study of LNS8801 in combination with pembrolizumab in patients with secondary resistance to immune checkpoint inhibitors. 2022, a791-a791. DOI: 10.1136/jitc-2022-sitc2022.0759.Peer-Reviewed Original Research
2020
807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors
Marabelle A, Champiat S, Garralda E, Hernando A, Janku F, Raina A, Sachse R, Bechard D, Krasnopolskaya I, Ferrara S, LoRusso P. 807 A multicenter open-label phase I/lb study of SO-C101 as monotherapy and in combination with pembrolizumab in patients with selected advanced/metastatic solid tumors. 2020, a483.1-a483. DOI: 10.1136/jitc-2020-sitc2020.0807.Peer-Reviewed Original Research